[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BR112015023417A2 - compostos heterocíclicos e seus usos - Google Patents

compostos heterocíclicos e seus usos

Info

Publication number
BR112015023417A2
BR112015023417A2 BR112015023417A BR112015023417A BR112015023417A2 BR 112015023417 A2 BR112015023417 A2 BR 112015023417A2 BR 112015023417 A BR112015023417 A BR 112015023417A BR 112015023417 A BR112015023417 A BR 112015023417A BR 112015023417 A2 BR112015023417 A2 BR 112015023417A2
Authority
BR
Brazil
Prior art keywords
heterocyclic compounds
preparation
methods
pharmaceutical formulations
uses certain
Prior art date
Application number
BR112015023417A
Other languages
English (en)
Other versions
BR112015023417B1 (pt
Inventor
Bi Mingda
Kuehl Robert
Original Assignee
Amgen Inc
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50549466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015023417(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc, Cytokinetics Inc filed Critical Amgen Inc
Publication of BR112015023417A2 publication Critical patent/BR112015023417A2/pt
Publication of BR112015023417B1 publication Critical patent/BR112015023417B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Inorganic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

1/1 resumo compostos heterocíclicos e seus usos são fornecidas certas formulações farmacêuticas de omecamtiv mecarbil e métodos para a sua preparação e utilização.
BR112015023417-8A 2013-03-14 2014-03-14 Formulação farmacêutica oral compreendendo hidrato de dicloridrato de omecamtiv mecarbil BR112015023417B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361785763P 2013-03-14 2013-03-14
US61/785,763 2013-03-14
PCT/US2014/027104 WO2014152236A1 (en) 2013-03-14 2014-03-14 Heterocyclic compounds and their uses

Publications (2)

Publication Number Publication Date
BR112015023417A2 true BR112015023417A2 (pt) 2017-07-18
BR112015023417B1 BR112015023417B1 (pt) 2023-10-17

Family

ID=50549466

Family Applications (2)

Application Number Title Priority Date Filing Date
BR112015022857-7A BR112015022857B1 (pt) 2013-03-14 2014-03-14 Sal de omecamtiv mecarbil e processo para preparar sal
BR112015023417-8A BR112015023417B1 (pt) 2013-03-14 2014-03-14 Formulação farmacêutica oral compreendendo hidrato de dicloridrato de omecamtiv mecarbil

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BR112015022857-7A BR112015022857B1 (pt) 2013-03-14 2014-03-14 Sal de omecamtiv mecarbil e processo para preparar sal

Country Status (41)

Country Link
US (14) US9988354B2 (pt)
EP (3) EP3821882A1 (pt)
JP (5) JP6498658B2 (pt)
KR (2) KR102374159B1 (pt)
CN (3) CN105209437B (pt)
AP (1) AP2015008789A0 (pt)
AR (2) AR095542A1 (pt)
AU (2) AU2014240049C1 (pt)
BR (2) BR112015022857B1 (pt)
CA (3) CA3147180C (pt)
CL (1) CL2015002708A1 (pt)
CR (1) CR20150549A (pt)
CY (2) CY1122695T1 (pt)
DK (2) DK2970123T3 (pt)
EA (1) EA031185B1 (pt)
ES (2) ES2750676T3 (pt)
HK (4) HK1218080A1 (pt)
HR (2) HRP20191728T1 (pt)
HU (2) HUE052355T2 (pt)
IL (2) IL240788B (pt)
JO (1) JOP20140114B1 (pt)
LT (2) LT2968173T (pt)
MA (2) MA38399B2 (pt)
ME (1) ME03566B (pt)
MX (3) MX363347B (pt)
MY (1) MY186048A (pt)
NZ (1) NZ711225A (pt)
PE (1) PE20151786A1 (pt)
PH (2) PH12015501998B1 (pt)
PL (2) PL2970123T3 (pt)
PT (2) PT2970123T (pt)
RS (2) RS61215B1 (pt)
RU (1) RU2663663C2 (pt)
SA (1) SA515361088B1 (pt)
SG (2) SG11201507258PA (pt)
SI (2) SI2968173T1 (pt)
TN (1) TN2015000380A1 (pt)
TW (1) TWI667026B (pt)
UA (1) UA117011C2 (pt)
UY (1) UY35449A (pt)
WO (2) WO2014152236A1 (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR095542A1 (es) * 2013-03-14 2015-10-21 Amgen Inc Compuestos heterocíclicos y sus usos
TWI790189B (zh) 2015-01-02 2023-01-21 美商梅拉洛伊卡公司 細菌組成物
EP3313444B1 (en) 2015-06-26 2020-10-21 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
TWI847144B (zh) * 2017-06-30 2024-07-01 美商安進公司 奧美卡替莫卡必爾的合成
JP2020526483A (ja) 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
EA039850B1 (ru) * 2018-04-30 2022-03-21 Эмджен Инк. Синтез омекамтива мекарбила
PL3594199T3 (pl) 2018-07-09 2020-11-16 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
US11608318B2 (en) * 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
JP2021534138A (ja) * 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
US20220185791A1 (en) * 2019-03-12 2022-06-16 Amgen Inc. Polymorphs of a cardiac troponin activator
EP3938041A1 (en) * 2019-03-12 2022-01-19 Amgen Inc. Polymorphs and cocrystals of a cardiac troponin activator
EP4045492A1 (en) 2019-09-19 2022-08-24 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070123A1 (en) * 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
IL295490A (en) * 2020-02-10 2022-10-01 Amgen Inc omecamtiv mecarbil tablet
US20220184068A1 (en) 2020-11-12 2022-06-16 Cytokinetics, Inc. Methods of treating heart failure by administering omecamtiv mecarbil
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
BR112023018095A2 (pt) 2021-03-10 2023-12-12 Amgen Inc Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo
WO2024081611A1 (en) 2022-10-11 2024-04-18 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators
US11986474B1 (en) 2023-06-27 2024-05-21 Cytokinetics, Incorporated Methods for treating heart failure by administering cardiac sarcomere activators

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2788775B1 (fr) * 1999-01-22 2001-04-13 Pf Medicament Nouvelles n-alcoyl-n-[1-(omega-(arylalcoyloxy)alcoyl] piperidin-4-yl]-4h-3,1-benzo(thia/oxa)zines-2-amines substituees, leur preparation et leur application en therapeutique
CZ20022046A3 (cs) 1999-12-23 2002-11-13 Pfizer Products Inc. Hydrogelem hnaná dávková forma účinné sloľky
GB0124455D0 (en) 2001-10-11 2001-12-05 Pfizer Ltd Pharmaceutical formulations
WO2003032965A2 (en) 2001-10-17 2003-04-24 King Pharmaceuticals Research And Development, Inc Use of ace inhibitors for reducing type 2 diabetes in high risk patients
US20050096365A1 (en) 2003-11-03 2005-05-05 David Fikstad Pharmaceutical compositions with synchronized solubilizer release
PT1765327E (pt) * 2004-06-17 2014-11-24 Cytokinetics Inc Compostos, composições e métodos
WO2007054975A1 (en) 2005-11-08 2007-05-18 Panacea Biotec Ltd Pharmaceutical compositions for the treatment of cardiovascular and other associated disorders
PE20100742A1 (es) 2005-11-15 2010-11-25 Glaxo Group Ltd Nuevos procedimientos y formulaciones
WO2007070683A2 (en) * 2005-12-15 2007-06-21 Cytokinetics, Inc. Certain chemical entities, compositions and methods
US20070208000A1 (en) 2005-12-15 2007-09-06 Morgan Bradley P Certain chemical entities, compositions and methods
WO2007078839A2 (en) * 2005-12-19 2007-07-12 Cytokinetics, Inc. Compounds, compositions and methods
US7639112B2 (en) 2007-04-25 2009-12-29 Sony Corporation Fuse device with integrated switch
US20090192168A1 (en) * 2008-01-04 2009-07-30 Alex Muci Compounds, Compositions and Methods
TW201006816A (en) * 2008-05-15 2010-02-16 Organon Nv Hexafluoroisopropanol derivatives
JP5591245B2 (ja) 2008-10-03 2014-09-17 ペリコー セラピューティクス， インコーポレイテッド 急性心不全の治療のための方法および組成物
US9253433B2 (en) 2012-11-27 2016-02-02 International Business Machines Corporation Method and apparatus for tagging media with identity of creator or scene
AR095542A1 (es) * 2013-03-14 2015-10-21 Amgen Inc Compuestos heterocíclicos y sus usos
JP6634368B2 (ja) * 2013-03-14 2020-01-22 アムジエン・インコーポレーテツド 複素環式化合物及びそれらの使用
WO2016123291A1 (en) 2015-01-29 2016-08-04 Signal Pharmaceuticals, Llc Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
EP3313444B1 (en) 2015-06-26 2020-10-21 Amgen Inc. Combination therapy of cardiac myosin activator and sinus node if current inhibitor
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
TWI847144B (zh) 2017-06-30 2024-07-01 美商安進公司 奧美卡替莫卡必爾的合成
PL3594199T3 (pl) 2018-07-09 2020-11-16 F.I.S.- Fabbrica Italiana Sintetici S.P.A. Krystaliczny 2-fluoro-3-nitrotoluen i sposób jego wytwarzania
US11608318B2 (en) 2018-07-12 2023-03-21 Assia Chemical Industries Ltd. Solid state forms of Omecamtiv mecarbil and Omecamtiv mecarbil diHCl
JP2021534138A (ja) 2018-08-17 2021-12-09 アムジエン・インコーポレーテツド オメカムチブメカルビルの塩及び結晶形態
WO2020131574A1 (en) 2018-12-18 2020-06-25 Amgen Inc. Method of reducing aromatic nitro compounds
EP4045492A1 (en) 2019-09-19 2022-08-24 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021053189A1 (en) 2019-09-19 2021-03-25 Synthon B.V. Salts of omecamtiv mecarbil and solid forms thereof
WO2021070123A1 (en) 2019-10-09 2021-04-15 Dr. Reddy’S Laboratories Limited Solid forms of omecamtiv mecarbil dihydrochloride and processes thereof
US20220411374A1 (en) 2019-10-09 2022-12-29 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of omecamtiv mecarbil
CN114929671B (zh) 2020-01-03 2024-04-16 苏州科睿思制药有限公司 化合物i二盐酸盐的共晶及其制备方法和用途
IL295490A (en) 2020-02-10 2022-10-01 Amgen Inc omecamtiv mecarbil tablet
US20220184068A1 (en) 2020-11-12 2022-06-16 Cytokinetics, Inc. Methods of treating heart failure by administering omecamtiv mecarbil
WO2022177927A1 (en) 2021-02-16 2022-08-25 Assia Chemical Industries Ltd Unhydrous crystalline form of omecamtiv mecarbil dihydrobromide salt
BR112023018095A2 (pt) 2021-03-10 2023-12-12 Amgen Inc Processos para sintetizar 2-fluoro-3-nitrotolueno, 1-(bromometil)-2-fluoro-3-nitrobenzeno e para preparar omecamtiv mecarbil ou um sal do mesmo, um hidrato do mesmo ou um hidrato de sal do mesmo

Also Published As

Publication number Publication date
EP3821882A1 (en) 2021-05-19
NZ750950A (en) 2020-09-25
IL240788A0 (en) 2015-10-29
US10421726B2 (en) 2019-09-24
BR112015022857A2 (pt) 2017-07-18
US20240317687A1 (en) 2024-09-26
SA515361088B1 (ar) 2018-07-22
RU2663663C2 (ru) 2018-08-08
JP6966590B2 (ja) 2021-11-17
PL2970123T3 (pl) 2020-03-31
BR112015023417B1 (pt) 2023-10-17
RS61215B1 (sr) 2021-01-29
KR102374159B1 (ko) 2022-03-15
EP2970123B1 (en) 2019-08-14
HUE052355T2 (hu) 2021-04-28
MA38399A1 (fr) 2017-01-31
IL240788B (en) 2020-09-30
PT2970123T (pt) 2019-10-28
KR20150136063A (ko) 2015-12-04
CN108785265A (zh) 2018-11-13
AU2014240049B2 (en) 2018-07-19
US11472773B2 (en) 2022-10-18
JP2016519071A (ja) 2016-06-30
IL241089A0 (en) 2015-11-30
PH12019500176A1 (en) 2020-11-04
US20180312469A1 (en) 2018-11-01
US20240217933A1 (en) 2024-07-04
CR20150549A (es) 2016-01-04
US20220298114A1 (en) 2022-09-22
CA2902436A1 (en) 2014-09-25
CA3147180C (en) 2024-04-23
EA201591728A1 (ru) 2016-01-29
CA2902646C (en) 2022-08-16
US20180273479A1 (en) 2018-09-27
EP2968173A1 (en) 2016-01-20
MY186048A (en) 2021-06-17
LT2970123T (lt) 2019-11-11
ES2837038T3 (es) 2021-06-29
MX2021001231A (es) 2021-04-12
PE20151786A1 (es) 2015-12-11
UY35449A (es) 2014-09-30
CY1122695T1 (el) 2021-03-12
CA2902646A1 (en) 2014-09-25
HUE046285T2 (hu) 2020-02-28
ME03566B (me) 2020-07-20
MX2015012429A (es) 2016-04-07
SI2970123T1 (sl) 2019-12-31
US20200331859A1 (en) 2020-10-22
AU2014239995A1 (en) 2015-09-10
JP6783138B2 (ja) 2020-11-11
US11958809B2 (en) 2024-04-16
US9951015B2 (en) 2018-04-24
CN108785265B (zh) 2024-10-08
HK1218544A1 (zh) 2017-02-24
JP6498658B2 (ja) 2019-04-10
JP7174132B2 (ja) 2022-11-17
US20160016906A1 (en) 2016-01-21
SI2968173T1 (sl) 2021-04-30
PL2968173T3 (pl) 2021-03-08
JOP20140114B1 (ar) 2021-08-17
IL241089B (en) 2019-10-31
MX2015012414A (es) 2016-04-25
WO2014152270A1 (en) 2014-09-25
AU2014240049A1 (en) 2015-09-10
RU2015143643A (ru) 2017-04-18
JP6689942B2 (ja) 2020-04-28
CL2015002708A1 (es) 2016-03-11
PH12015501998A1 (en) 2016-01-11
CN105209437A (zh) 2015-12-30
US20200399221A1 (en) 2020-12-24
JP2019059746A (ja) 2019-04-18
UA117011C2 (uk) 2018-06-11
US20140309235A1 (en) 2014-10-16
AU2014239995B2 (en) 2018-07-26
EP2968173B1 (en) 2020-10-14
TWI667026B (zh) 2019-08-01
HK1219484A1 (zh) 2017-04-07
KR20220045014A (ko) 2022-04-12
US9988354B2 (en) 2018-06-05
ES2750676T3 (es) 2020-03-26
NZ711225A (en) 2020-06-26
US20200277261A1 (en) 2020-09-03
JP2020125307A (ja) 2020-08-20
SG10201706656RA (en) 2017-09-28
US20240101517A1 (en) 2024-03-28
US11884630B2 (en) 2024-01-30
AR129504A2 (es) 2024-09-04
WO2014152236A1 (en) 2014-09-25
HK1218080A1 (zh) 2017-02-03
DK2968173T3 (da) 2020-12-21
EA031185B1 (ru) 2018-11-30
JP2016513683A (ja) 2016-05-16
JP2022023891A (ja) 2022-02-08
TW201524507A (zh) 2015-07-01
AP2015008789A0 (en) 2015-10-31
CN105120844A (zh) 2015-12-02
HRP20191728T1 (hr) 2019-12-13
AR095542A1 (es) 2015-10-21
CY1123633T1 (el) 2022-03-24
HK1218512A1 (zh) 2017-02-24
KR102474467B1 (ko) 2022-12-05
TN2015000380A1 (en) 2017-01-03
MA44637B1 (fr) 2021-04-30
MX363347B (es) 2019-03-20
MA44637A1 (fr) 2019-08-30
US20220153700A1 (en) 2022-05-19
CN105209437B (zh) 2018-09-18
HRP20201967T1 (hr) 2021-03-05
LT2968173T (lt) 2021-03-25
MA38399B2 (fr) 2020-12-31
US20230044617A1 (en) 2023-02-09
SG11201507258PA (en) 2015-10-29
DK2970123T3 (da) 2019-10-21
PH12015501998B1 (en) 2016-01-11
EP2970123A1 (en) 2016-01-20
RS59536B1 (sr) 2019-12-31
US11384053B2 (en) 2022-07-12
PT2968173T (pt) 2020-12-18
US20200079736A1 (en) 2020-03-12
BR112015022857B1 (pt) 2022-10-25
AU2014240049C1 (en) 2019-03-07
CA3147180A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
BR112015023417A2 (pt) compostos heterocíclicos e seus usos
DOP2015000051A (es) Formulaciones acuosas estables de adalimumab
BR112016016158A2 (pt) Derivados de heterociclila bicíclicos como inibidores de irak4, sua composição farmacêutica e seus usos
UY35485A (es) Compuestos heterocíclicos y usos de los mismos
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
UY34542A (es) ?formulaciones farmacéuticas para conjugados de derivados de fumagilina y phf?.
MA50541A (fr) Formulations pharmaceutiques
GT201700023A (es) Derivados de heterociclico opcionalmente condensados de piridimina útiles para el tratamiento de enfermedades inflamatorias, metabolicas, oncológicas y autoinmunitarias
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
NI201500096A (es) Compuesto químicos
MA42303A (fr) Formulations pharmaceutiques
MX2015012416A (es) Compuestos heterociclicos y sus usos.
MA46867A (fr) Formulations pharmaceutiques
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
FR3013218B1 (fr) Composition comprenant des capsules gelifiees stabilisees par un tampon
CL2017000587A1 (es) Derivados de tetrahidroquinolina como inhibidores de bromodominio
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
UY36117A (es) Composiciones farmacéuticas para el tratamiento de enfermedades infecciosas.
CY1121105T1 (el) Φαρμακοτεχνικη μορφη αταζαναβιρης και κομπισιστατης για θεραπεια hiv
BR112016027383A2 (pt) Derivados de naftiridinadiona, seus usos, composição farmacêutica e combinação
BR112016012002A2 (pt) Vitanolídeos úteis para o tratamento de doenças neurodegenerativas
CY1118277T1 (el) Σταθερη φαρμακοτεχνικη μορφη πεξιγανανης
BR112016020135A2 (pt) mistura de composto, seus usos, composição farmacêutica, e conjunto (kit)
DK3153163T3 (da) Farmaceutisk forbindelse der omfatter 13 glycerider, formulering og anvendelse deraf
BR112016026443A2 (pt) compostos heterocíclicos deuterados, seus usos, e composição farmacêutica

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/03/2014, OBSERVADAS AS CONDICOES LEGAIS